A citation-based method for searching scientific literature

Laszlo G Harsing, Istvan Gacsalyi, Geza Szabo, Eva Schmidt, Nora Sziray, Claude Sebban, Brigitte Tesolin-Decros, Peter Matyus, Andras Egyed, Michael Spedding, Gyorgy Levay. Pharmacol Biochem Behav 2003
Times Cited: 87







List of co-cited articles
1174 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.
Gene G Kinney, Cyrille Sur, Maryann Burno, Pierre J Mallorga, Jacinta B Williams, David J Figueroa, Marion Wittmann, Wei Lemaire, P Jeffrey Conn. J Neurosci 2003
145
58

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.
Ronan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Annick Coste, Christophe Lanneau, Christophe Desvignes, Martine Poncelet, Michel Heaulme, Vincent Santucci, Michel Decobert,[...]. Neuropsychopharmacology 2005
178
55

Modulation of N-methyl-D-aspartate receptor function by glycine transport.
R Bergeron, T M Meyer, J T Coyle, R W Greene. Proc Natl Acad Sci U S A 1998
336
50


Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
257
44


Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain.
Beatriz Cubelos, Cecilio Giménez, Francisco Zafra. Cereb Cortex 2005
220
42

ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter.
B N Atkinson, S C Bell, M De Vivo, L R Kowalski, S M Lechner, V I Ognyanov, C S Tham, C Tsai, J Jia, D Ashton,[...]. Mol Pharmacol 2001
145
41

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
41

Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor.
Gwenaëlle Le Pen, James Kew, Daniela Alberati, Edilio Borroni, Marie Paule Heitz, Jean-Luc Moreau. Biol Psychiatry 2003
92
37

Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels.
Marzia Martina, Yelena Gorfinkel, Samantha Halman, John A Lowe, Pranav Periyalwar, Christopher J Schmidt, Richard Bergeron. J Physiol 2004
133
36


Discovery and SAR of org 24598-a selective glycine uptake inhibitor.
A Brown, I Carlyle, J Clark, W Hamilton, S Gibson, G McGarry, S McEachen, D Rae, S Thorn, G Walker. Bioorg Med Chem Lett 2001
77
36

Glycine transporters are differentially expressed among CNS cells.
F Zafra, C Aragón, L Olivares, N C Danbolt, C Giménez, J Storm-Mathisen. J Neurosci 1995
417
31

Gene knockout of glycine transporter 1: characterization of the behavioral phenotype.
Guochuan Tsai, Rebecca J Ralph-Williams, Marzia Martina, Richard Bergeron, Joanne Berger-Sweeney, Kevin S Dunham, Zhichun Jiang, S Barak Caine, Joseph T Coyle. Proc Natl Acad Sci U S A 2004
155
31

Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition.
Jesús Gomeza, Swen Hülsmann, Koji Ohno, Volker Eulenburg, Katalin Szöke, Diethelm Richter, Heinrich Betz. Neuron 2003
233
28

Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors.
K E Smith, L A Borden, P R Hartig, T Branchek, R L Weinshank. Neuron 1992
388
27

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
208
27



Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.
Benjamin K Yee, Ela Balic, Philipp Singer, Cornelia Schwerdel, Thomas Grampp, Laetitia Gabernet, Irene Knuesel, Dietmar Benke, Joram Feldon, Hanns Mohler,[...]. J Neurosci 2006
114
26

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Kenneth W Perry, Julie F Falcone, Matthew J Fell, John W Ryder, Hong Yu, Patrick L Love, Jason Katner, Kimberly D Gordon, Mark R Wade, Teresa Man,[...]. Neuropharmacology 2008
70
32




Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein. Arch Gen Psychiatry 1999
352
24


Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists.
Daniel C Javitt, Andrea Balla, Sarah Burch, Ray Suckow, Shan Xie, Henry Sershen. Neuropsychopharmacology 2004
79
26

Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia.
Denis Boulay, Philippe Pichat, Gihad Dargazanli, Genevieve Estenne-Bouhtou, Jean Paul Terranova, Nancy Rogacki, Jeanne Stemmelin, Annick Coste, Christophe Lanneau, Christophe Desvignes,[...]. Pharmacol Biochem Behav 2008
71
29

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
497
22

Glycine transporters: essential regulators of neurotransmission.
Volker Eulenburg, Wencke Armsen, Heinrich Betz, Jesús Gomeza. Trends Biochem Sci 2005
241
22

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Pesah Lichtenberg, Gali Bar, Daniel C Javitt. Biol Psychiatry 2004
170
21

Glycine transporter type-1 and its inhibitors.
L G Harsing, Z Juranyi, I Gacsalyi, P Tapolcsanyi, A Czompa, P Matyus. Curr Med Chem 2006
54
35



The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
290
20

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study.
Hsien-Yuan Lane, Yi-Ching Liu, Chieh-Liang Huang, Yue-Cune Chang, Chun-Hui Liau, Cheng-Hwang Perng, Guochuan E Tsai. Biol Psychiatry 2008
114
20

Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.
Mark D Black, Geoffrey B Varty, Michal Arad, Segev Barak, Amaya De Levie, Denis Boulay, Philippe Pichat, Guy Griebel, Ina Weiner. Psychopharmacology (Berl) 2009
68
26

Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine.
Pierre J Mallorga, Jacinta B Williams, Marlene Jacobson, Rosemary Marques, Ashok Chaudhary, P Jeffrey Conn, Douglas J Pettibone, Cyrille Sur. Neuropharmacology 2003
53
32

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
19

Glycine binding primes NMDA receptor internalization.
Yi Nong, Yue-Qiao Huang, William Ju, Lorraine V Kalia, Gholamreza Ahmadian, Yu Tian Wang, Michael W Salter. Nature 2003
312
19


Adjunctive high-dose glycine in the treatment of schizophrenia.
D C Javitt, G Silipo, A Cienfuegos, A M Shelley, N Bark, M Park, J P Lindenmayer, R Suckow, S R Zukin. Int J Neuropsychopharmacol 2001
121
18

Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression.
Laetitia Gabernet, Meike Pauly-Evers, Cornelia Schwerdel, Michèle Lentz, Horst Bluethmann, Kaspar Vogt, Daniela Alberati, Hanns Mohler, Detlev Boison. Neurosci Lett 2005
73
21

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
260
18







Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.